title: Predictors of ovarian reserve in young women with breast cancer.
abstract: Ovarian reserve can be diminished following treatment for breast cancer. This study evaluated biochemical and biophysical parameters of ovarian reserve in these patients. Biochemical and biophysical tests of ovarian reserve were performed simultaneously in young (age 22-42 years), regularly menstruating women with breast cancer (n=22) and age-matched controls (n=24). All tests were performed before (baseline) and after transient ovarian stimulation in the early follicular phase. Patients were recruited both before and after completion of chemotherapy, with some patients being followed up prospectively. Serum samples were analysed for follicle-stimulating hormone (FSH), luteinising hormone (LH), oestradiol (E(2)), inhibins A and B, and antimullerian hormone (AMH). Biophysical (ultrasound) tests included ovarian volume, antral follicle count (AFC), ovarian stromal blood flow and uterine dimensions. Significant differences were revealed (when compared with the controls) for basal FSH (11.32+/-1.48 vs 6.62+/-0.42 mIU ml(-1), P<0.001), basal AMH (0.95+/-0.34 vs 7.89+/-1.62 ng ml(-1), P<0.001) and basal inhibin B (19.24+/-4.56 vs 83.61+/-13.45 pg ml(-1), P<0.001). Following transient ovarian stimulation, there were significant differences in the increment change (Delta) for inhibin B (3.02+/-2.3 vs 96.82+/-16.38 pg ml(-1), P<0.001) and E(2) (107.8+/-23.95 vs 283.2+/-40.34 pg ml(-1), P<0.01). AFC was the only biophysical parameter that was significantly different between patients and the controls (7.80+/-0.85 vs 16.77+/-1.11, P<0.001). Basal and stimulated biochemical (serum AMH, FSH, inhibin B and E(2)) and biophysical (AFC) tests may be potential markers of ovarian reserve in young women with breast cancer.
authors.affiliation: Department of Obstetrics and Gynaecology, Royal Free and University College London Medical School, 86-96 Chenies Mews, London WC1E 6HX, UK. k.lutchman-singh@ucl.ac.uk
authors.forename: K
authors.initials: K
authors.lastname: Lutchman Singh
authors.forename: S
authors.initials: S
authors.lastname: Muttukrishna
authors.forename: R C
authors.initials: RC
authors.lastname: Stein
authors.forename: H H
authors.initials: HH
authors.lastname: McGarrigle
authors.forename: A
authors.initials: A
authors.lastname: Patel
authors.forename: B
authors.initials: B
authors.lastname: Parikh
authors.forename: N P
authors.initials: NP
authors.lastname: Groome
authors.forename: M C
authors.initials: MC
authors.lastname: Davies
authors.forename: R
authors.initials: R
authors.lastname: Chatterjee
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D006080:Ovarian Follicle / Q000187:drug effects / Q000473:pathology; D010050:Ovarian Function Tests; D010053:Ovary / Q000187:drug effects / Q000503:physiopathology*
chemical_list: D000970:Antineoplastic Agents